Each week (well almost, some weeks are quite uneventful), we compile and curate hot-off-the-press news and updates on the happenings in the world of pharma and life sciences partnering.
Be sure to follow us and keep up-to-date on all things partnering to inform your decisions and strategies.
Gilead Sciences signs deal with Dragonfly Therapeutics for natural killer (NK) cell category, paying $300 million upfront to access TriNKET platform — see full article.pharmaphorum.com
Byondis B.V., a Dutch clinical stage biopharmaceutical company, has signed a License and Collaboration Agreement and a Supply Agreement with medac GmbH — see full article.contractpharma.com
Protagonist presents Q1 2022 financial results and shares topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis — see full article.protagonist-inc.com
Alcami, a US-based CDMO and Civica Inc., a nonprofit pharma, enter into multi-year partnering agreement — see full article.alcaminow.com
Jazz and Sumitomo Pharma enter into exclusive license agreement to develop and commercialize sleep disorder therapies — see full article.jazzpharma.com
Illumina, Inc., a DNA sequencing and array-based technologies company, and Deerfield Management announced a five-year partnership to focus on genetic-led drug discovery and development — see full article.illumina.com